Precision Optics Corporation Earnings Call Transcripts
Fiscal Year 2026
-
Q2 FY2026 revenue hit a record $7.4M, led by aerospace and single-use medical device programs. Gross margin fell to 2.8% due to manufacturing inefficiencies, but operational improvements and strong bookings signal margin recovery and growth in H2. Full-year revenue guidance was raised to $26–$28M.
-
Record Q1 revenue of $6.7M was driven by aerospace and surgical robotics programs, with strong backlog and margin improvements expected as production scales. Fiscal 2026 revenue is projected to exceed $25M, with positive adjusted EBITDA despite a Q1 loss.
Fiscal Year 2025
-
Precision Optics is experiencing a pivotal shift as major programs transition from development to manufacturing, driving a projected 30%+ revenue increase to $25 million in fiscal 2026. Manufacturing growth, a record $18 million backlog, and operational investments are expected to restore margins and positive EBITDA.
-
Record Q4 revenue and a strong production backlog set the stage for over 30% revenue growth and a gross margin rebound to 30% in fiscal 2026, driven by aerospace and medical programs. Operational investments and new leadership aim to support scaling and profitability.
-
The company leverages proprietary micro-optics, ultra-precision, and digital imaging technologies to drive growth in medical devices and defense/aerospace, with a focus on single-use endoscopes and robust customer retention. Recent manufacturing expansion and the Unity platform aim to accelerate product development and support increasing demand.
-
The company is at an inflection point, shifting from product development to high-volume manufacturing, driven by major programs in single-use medical devices and aerospace. Revenue growth is expected to accelerate as new programs enter production, supported by expanded facilities and a robust pipeline.
-
Q3 saw lower revenue and margins due to production issues, but backlog and demand remain strong. The Unity platform launch and a major aerospace contract support a positive Q4 outlook, with revenue expected to rebound and adjusted EBITDA turning positive.
-
Proprietary Micro-Optics and imaging technologies drive growth in medical and defense markets, with two major programs recently entering production and a new Unity platform accelerating development. Revenue and backlog are set to increase, supported by expanded facilities and strategic partnerships.
-
Precision Optics is leveraging proprietary micro-optics and digital imaging to drive growth in medical and defense markets, with a focus on single-use endoscopes and the new Unity platform to accelerate development. Major production orders and a robust pipeline position the company for continued expansion.
-
Production revenue surged 42% sequentially, driven by single-use cystoscope and defense aerospace programs, with record backlogs and the launch of the Unity Imaging Platform. Q2 revenue was $4.5M, with Q4 forecasted at $6M and positive adjusted EBITDA expected.
-
Q1 revenue and margins were impacted by production delays, but issues are resolved and strong growth is expected in Q2 and beyond. Major single-use endoscope programs are entering production, supporting a robust long-term outlook and increased recurring revenue.
Fiscal Year 2024
-
Precision Optics is leveraging its expertise in micro-optics, 3D endoscopes, and digital imaging to drive growth in medical and defense markets. Despite a recent revenue dip, a robust product development pipeline and new production programs position the company for record growth in fiscal 2025.
-
Fiscal 2024 revenue was $19.1 million, down year-over-year due to program losses and industry headwinds, but product development hit record levels. Operational challenges in Q4 and Q1 are largely resolved, with strong revenue and margin growth expected in Q2 and beyond.